Seminars in liver disease最新文献_第5页

Role of Neutrophils in the Development of Steatotic Liver Disease. 中性粒细胞在脂肪肝发病过程中的作用

IF 4.3 3区医学

Seminars in liver disease Pub Date : 2024-08-01 Epub Date: 2024-08-08 DOI: 10.1055/s-0044-1789207

You-Jin Choi, Yeonsoo Kim, Seonghwan Hwang

引用次数: 0

Combined Organ Transplantation in Patients with Advanced Liver Disease. 晚期肝病患者的联合器官移植。

IF 4.3 3区医学

Seminars in liver disease Pub Date : 2024-08-01 Epub Date: 2024-07-25 DOI: 10.1055/s-0044-1788674

Ingrid Wei Zhang, Isabella Lurje, Georg Lurje, Christoph Knosalla, Felix Schoenrath, Frank Tacke, Cornelius Engelmann

{"title":"Combined Organ Transplantation in Patients with Advanced Liver Disease.","authors":"Ingrid Wei Zhang, Isabella Lurje, Georg Lurje, Christoph Knosalla, Felix Schoenrath, Frank Tacke, Cornelius Engelmann","doi":"10.1055/s-0044-1788674","DOIUrl":"10.1055/s-0044-1788674","url":null,"abstract":"Transplantation of the liver in combination with other organs is an increasingly performed procedure. Over the years, continuous improvement in survival could be realized through careful patient selection and refined organ preservation techniques, in spite of the challenges posed by aging recipients and donors, as well as the increased use of steatotic liver grafts. Herein, we revisit the epidemiology, allocation policies in different transplant zones, indications, and outcomes with regard to simultaneous organ transplants involving the liver, that is combined heart-liver, liver-lung, liver-kidney, and multivisceral transplantation. We address challenges surrounding combined organ transplantation such as equity, utility, and logistics of dual organ implantation, but also advantages that come along with combined transplantation, thereby focusing on molecular mechanisms underlying immunoprotection provided by the liver to the other allografts. In addition, the current standing and knowledge of machine perfusion in combined organ transplantation, mostly based on center experience, will be reviewed. Notwithstanding all the technical advances, shortage of organs, and the lack of universal eligibility criteria for certain multi-organ combinations are hurdles that need to be tackled in the future.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"369-382"},"PeriodicalIF":4.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449526/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141760838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Statins in Chronic Liver Disease: Review of the Literature and Future Role. 他汀类药物在慢性肝病中的应用：文献综述与未来作用。

IF 4.3 3区医学

Seminars in liver disease Pub Date : 2024-05-01 Epub Date: 2024-05-03 DOI: 10.1055/a-2319-0694

Nguyen Pham, Jihane N Benhammou

引用次数: 0

Hepatotoxicity of Antibiotics and Antifungals and Their Safe Use in Hepatic Impairment. 抗生素和抗真菌药的肝毒性及其在肝功能受损情况下的安全使用。

IF 4.3 3区医学

Seminars in liver disease Pub Date : 2024-05-01 Epub Date: 2024-05-13 DOI: 10.1055/s-0044-1787062

J Ma, E S Björnsson, N Chalasani

引用次数: 0

Molecular Genealogy of Metabolic-associated Hepatocellular Carcinoma. 代谢相关肝细胞癌的分子谱系。

IF 4.3 3区医学

Seminars in liver disease Pub Date : 2024-05-01 Epub Date: 2024-03-18 DOI: 10.1055/a-2289-2298

Takahiro Kodama, Tetsuo Takehara

{"title":"Molecular Genealogy of Metabolic-associated Hepatocellular Carcinoma.","authors":"Takahiro Kodama, Tetsuo Takehara","doi":"10.1055/a-2289-2298","DOIUrl":"10.1055/a-2289-2298","url":null,"abstract":"This review examines the latest epidemiological and molecular pathogenic findings of metabolic-associated hepatocellular carcinoma (HCC). Its increasing prevalence is a significant concern and reflects the growing burden of obesity and metabolic diseases, including metabolic dysfunction-associated steatotic liver disease, formerly known as nonalcoholic fatty liver disease, and type 2 diabetes. Metabolic-associated HCC has unique molecular abnormality and distinctive gene expression patterns implicating aberrations in bile acid, fatty acid metabolism, oxidative stress, and proinflammatory pathways. Furthermore, a notable frequency of single nucleotide polymorphisms in genes such as patatin-like phospholipase domain-containing 3, transmembrane 6 superfamily member 2, glucokinase regulator, and membrane-bound O-acyltransferase domain-containing 7 has been observed. The tumor immune microenvironment of metabolic-associated HCC is characterized by unique phenotypes of macrophages, neutrophils, and T lymphocytes. Additionally, the pathogenesis of metabolic-associated HCC is influenced by abnormal lipid metabolism, insulin resistance, and dysbiosis. In conclusion, deciphering the intricate interactions among metabolic processes, genetic predispositions, inflammatory responses, immune regulation, and microbial ecology is imperative for the development of novel therapeutic and preventative measures against metabolic-associated HCC.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"147-158"},"PeriodicalIF":4.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11245329/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140158970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heterogeneity in Liver Cancer Immune Microenvironment: Emerging Single-Cell and Spatial Perspectives. 肝癌免疫微环境的异质性：新的单细胞和空间视角

IF 4.3 3区医学

Seminars in liver disease Pub Date : 2024-05-01 Epub Date: 2024-05-24 DOI: 10.1055/s-0044-1787152

Caiyi Cherry Li, Meng Liu, Hsin-Pei Lee, Wenqi Wu, Lichun Ma

引用次数: 0

This Is What Metabolic Dysfunction-Associated Steatotic Liver Disease Looks Like: Potential of a Multiparametric MRI Protocol. 这就是 MASLD 的样子：多参数磁共振成像方案的潜力。

IF 4.3 3区医学

Seminars in liver disease Pub Date : 2024-05-01 Epub Date: 2024-05-28 DOI: 10.1055/a-2334-8525

Anja M Fischer, Nazim Lechea, Harvey O Coxson

{"title":"This Is What Metabolic Dysfunction-Associated Steatotic Liver Disease Looks Like: Potential of a Multiparametric MRI Protocol.","authors":"Anja M Fischer, Nazim Lechea, Harvey O Coxson","doi":"10.1055/a-2334-8525","DOIUrl":"10.1055/a-2334-8525","url":null,"abstract":"Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent condition with a broad spectrum defined by liver biopsy. This gold standard method evaluates three features: steatosis, activity (ballooning and lobular inflammation), and fibrosis, attributing them to certain grades or stages using a semiquantitative scoring system. However, liver biopsy is subject to numerous restrictions, creating an unmet need for a reliable and reproducible method for MASLD assessment, grading, and staging. Noninvasive imaging modalities, such as magnetic resonance imaging (MRI), offer the potential to assess quantitative liver parameters. This review aims to provide an overview of the available MRI techniques for the three criteria evaluated individually by liver histology. Here, we discuss the possibility of combining multiple MRI parameters to replace liver biopsy with a holistic, multiparametric MRI protocol. In conclusion, the development and implementation of such an approach could significantly improve the diagnosis and management of MASLD, reducing the need for invasive procedures and paving the way for more personalized treatment strategies.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"226-238"},"PeriodicalIF":4.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141162458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is There a Safe Alcohol Consumption Limit for the General Population and in Patients with Liver Disease? 一般人群和肝病患者是否有安全的饮酒限量？

IF 4.2 3区医学

Seminars in liver disease Pub Date : 2024-04-04 DOI: 10.1055/s-0044-1785228

Manuel Romero-Gómez, Juan Pablo Arab, Claudia P. Oliveira, María Hernández, Marco Arrese, Helena Cortez-Pinto, Ramón Bataller

{"title":"Is There a Safe Alcohol Consumption Limit for the General Population and in Patients with Liver Disease?","authors":"Manuel Romero-Gómez, Juan Pablo Arab, Claudia P. Oliveira, María Hernández, Marco Arrese, Helena Cortez-Pinto, Ramón Bataller","doi":"10.1055/s-0044-1785228","DOIUrl":"https://doi.org/10.1055/s-0044-1785228","url":null,"abstract":"Excessive alcohol consumption represents an important burden for health systems worldwide and is a major cause of liver- and cancer-related deaths. Alcohol consumption is mostly assessed by self-report that often underestimates the amount of drinking. While alcohol use disorders identification test - version C is the most widely used test for alcohol use screening, in patients with liver disease the use of alcohol biomarker could help an objective assessment. The amount of alcohol that leads to significant liver disease depends on gender, genetic background, and coexistence of comorbidities (i.e., metabolic syndrome factors). All patients with alcohol-associated liver disease are recommended to follow complete abstinence and they should be treated within multidisciplinary teams. Abstinence slows down and even reverses the progression of liver fibrosis and can help recompensate patients with complicated cirrhosis. Whether there is a safe amount of alcohol in the general population is a matter of intense debate. Large epidemiological studies showed that the safe amount of alcohol to avoid overall health-related risks is lower than expected even in the general population. Even one drink per day can increase cancer-related death. In patients with any kind of chronic liver disease, especially in those with metabolic-associated steatotic liver disease, no alcohol intake is recommended. This review article discusses the current evidence supporting the deleterious effects of small-to-moderate amounts of alcohol in the general population and in patients with underlying chronic liver disease. ","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":"16 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140576443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice. 非酒精性脂肪肝的新命名法：了解代谢功能障碍相关性脂肪肝、代谢功能障碍和酒精相关性肝病及其在临床实践中的意义。

IF 4.2 3区医学

Seminars in liver disease Pub Date : 2024-02-01 Epub Date: 2024-03-26 DOI: 10.1055/s-0044-1785196

Clémence M Canivet, Jérôme Boursier, Rohit Loomba

{"title":"New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice.","authors":"Clémence M Canivet, Jérôme Boursier, Rohit Loomba","doi":"10.1055/s-0044-1785196","DOIUrl":"10.1055/s-0044-1785196","url":null,"abstract":"In June 2023, under the patronage of the American Association for Study of Liver Disease, the European Association for Study of the Liver, and the Asociación Latinoamericana para el Estudio del Hígado with the involvement of 236 participants from around the world, a new nomenclature and definition for nonalcoholic fatty liver disease (NAFLD) has been proposed. Metabolic dysfunction-associated steatotic liver disease (MASLD) was defined as presence of hepatic steatosis and at least one of the cardiometabolic risk factors with alcohol intake less than 140 g/wk for women and 210 g/wk for men and no other causes of steatosis. A new entity called combined metabolic dysfunction- and alcohol-associated liver disease (MetALD) was created outside of pure MASLD for patients with metabolic dysfunction and alcohol intake greater than that allowed for MASLD (i.e., 140-350 g/wk for women and 210-420 g/wk for men). Recent studies have confirmed a 95% overlap between NAFLD and the new MASLD diagnostic criteria. Natural history, biomarkers, and thresholds of alcohol intake in MetALD group remains to be studied and validated.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"35-42"},"PeriodicalIF":4.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140294465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease. 为 MASLD 患者量身定制的护理模式。

IF 4.2 3区医学

Seminars in liver disease Pub Date : 2024-02-01 Epub Date: 2024-01-25 DOI: 10.1055/a-2253-9181

Mohamed El-Kassas, Abeer Awad, Mohamed Elbadry, Juan Pablo Arab

{"title":"Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.","authors":"Mohamed El-Kassas, Abeer Awad, Mohamed Elbadry, Juan Pablo Arab","doi":"10.1055/a-2253-9181","DOIUrl":"10.1055/a-2253-9181","url":null,"abstract":"Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is increasing globally, creating a growing public health concern. However, this disease is often not diagnosed, and accurate data on its epidemiology are limited in many geographical regions, making it challenging to provide proper care and implement effective national plans. To combat the increasing disease burden, screening and diagnosis must reach a significant number of high-risk subjects. Addressing MASLD as a health care challenge requires a multidisciplinary approach involving prevention, diagnosis, treatment, and care, with collaboration between multiple stakeholders in the health care system. This approach must be guided by national and global strategies, to be combined with efficient models of care developed through a bottom-up process. This review article highlights the pillars of the MASLD model of care (MoC), including screening, risk stratification, and establishing a clinical care pathway for management, in addition to discussing the impact of nomenclature change on the proposed MoC.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"54-68"},"PeriodicalIF":4.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139565004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0